“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Wednesday, August 20, 2025

Anti-CTLA-4 monoclonal antibodies


Introduction

Immune checkpoint inhibitors have revolutionized cancer therapy by enhancing the body’s own immune response against tumor cells. Among these, anti-CTLA-4 monoclonal antibodies represent a pioneering class of drugs that target a fundamental immune checkpoint pathway. The cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) receptor plays a central role in downregulating immune activation, thereby preventing excessive immune responses. However, tumors exploit this pathway to evade immune detection. Anti-CTLA-4 antibodies block this inhibitory receptor, reactivating T-cell mediated immunity against cancer cells.

Currently, the major clinically approved representative of this class is ipilimumab. Other agents, such as tremelimumab, are undergoing regulatory approvals or clinical trials in different cancer types. These therapies are primarily used in advanced malignancies such as melanoma, renal cell carcinoma, hepatocellular carcinoma, mesothelioma, and non-small cell lung cancer (NSCLC), often in combination with other checkpoint inhibitors like anti-PD-1 antibodies.

Mechanism of Action

CTLA-4 is an immune checkpoint receptor expressed on activated T-cells. It functions as a negative regulator of T-cell activation by competing with the costimulatory receptor CD28 for binding to B7 ligands (CD80 and CD86) on antigen-presenting cells. When CTLA-4 binds to these ligands, it transmits an inhibitory signal that reduces T-cell proliferation and cytokine production.

Anti-CTLA-4 monoclonal antibodies, such as ipilimumab, block this inhibitory interaction, restoring CD28-mediated costimulation. This results in:

  • Enhanced T-cell activation and proliferation

  • Increased infiltration of T-cells into tumor microenvironments

  • Amplification of cytotoxic activity against cancer cells

However, this systemic activation of T-cells is not tumor-specific, which explains the high rate of immune-related adverse effects (irAEs) seen with these therapies.

Representative Agents

1. Ipilimumab (Yervoy®)

  • Generic Name: Ipilimumab

  • Drug Class: Anti-CTLA-4 monoclonal antibody (IgG1κ)

  • Indications:

    • Advanced (unresectable or metastatic) melanoma

    • Adjuvant therapy in resected melanoma

    • Combination therapy for renal cell carcinoma (RCC), NSCLC, small cell lung cancer (SCLC), mesothelioma, and hepatocellular carcinoma (HCC)

    • Investigational combinations in other malignancies

  • Mechanism: Binds CTLA-4 receptor, blocking its interaction with B7 ligands, thus enhancing T-cell immune response against tumors.

  • Formulation: Intravenous infusion

  • Standard Doses (adults):

    • Melanoma monotherapy: 3 mg/kg IV over 90 minutes every 3 weeks for 4 doses

    • Combination therapy (e.g., with nivolumab):

      • Ipilimumab 1 mg/kg IV every 3 weeks for 4 doses plus nivolumab, followed by nivolumab maintenance

      • In some regimens, ipilimumab 3 mg/kg is used with nivolumab 1 mg/kg depending on the indication

  • Pharmacokinetics:

    • Half-life: ~15 days

    • Clearance not significantly affected by renal or hepatic impairment

2. Tremelimumab (Imjudo®)

  • Generic Name: Tremelimumab-actl

  • Drug Class: Anti-CTLA-4 monoclonal antibody (IgG2)

  • Indications:

    • Recently approved in combination with durvalumab (anti-PD-L1 antibody) for unresectable hepatocellular carcinoma

    • Being investigated in NSCLC, mesothelioma, and urothelial carcinoma

  • Formulation: Intravenous infusion

  • Standard Doses (adults):

    • HCC (STRIDE regimen): A single priming dose of tremelimumab 300 mg IV on Day 1 (cycle 1) combined with durvalumab 1500 mg IV every 4 weeks, followed by durvalumab monotherapy

    • Mesothelioma (clinical trials): 75 mg IV every 4 weeks in combination with durvalumab

  • Pharmacokinetics:

    • Half-life: ~22 days

    • Similar clearance profile to ipilimumab

Clinical Uses

Anti-CTLA-4 monoclonal antibodies are predominantly used in oncology. The key therapeutic areas include:

  • Melanoma
    Ipilimumab was the first immune checkpoint inhibitor approved (2011) for advanced melanoma, showing survival benefit in previously untreatable patients. It remains a standard of care, often combined with nivolumab.

  • Renal Cell Carcinoma (RCC)
    Combination regimens of ipilimumab plus nivolumab are approved for advanced or intermediate-poor risk RCC.

  • Hepatocellular Carcinoma (HCC)
    Tremelimumab combined with durvalumab demonstrated significant survival improvement, leading to regulatory approval for advanced liver cancer.

  • Non-Small Cell Lung Cancer (NSCLC)
    Ipilimumab plus nivolumab (with or without chemotherapy) has demonstrated survival benefit in metastatic NSCLC.

  • Mesothelioma
    Both ipilimumab/nivolumab and tremelimumab/durvalumab combinations are approved for malignant pleural mesothelioma.

  • Other cancers under investigation: Prostate cancer, ovarian cancer, head and neck squamous cell carcinoma (HNSCC), colorectal cancer (especially MSI-H tumors).

Dosing Considerations

  • Dosing is typically weight-based (mg/kg) but can also be fixed (e.g., tremelimumab 300 mg single dose).

  • Premedication is not routinely required, but infusion-related reactions may occur.

  • Therapy must be administered in specialized oncology centers with experience in managing immune-related toxicities.

Contraindications

  • Known hypersensitivity to ipilimumab, tremelimumab, or formulation components

  • Patients with uncontrolled autoimmune disease (e.g., lupus, inflammatory bowel disease, severe rheumatoid arthritis) due to high risk of exacerbation

  • Caution in patients with prior severe immune-related toxicity from checkpoint inhibitors

Adverse Effects

Because these drugs broadly activate T-cells, adverse effects are largely immune-mediated. They may involve any organ system:

  • Gastrointestinal:

    • Colitis, diarrhea, GI perforation (severe, life-threatening in some cases)

    • Typically dose-dependent, occurring in ~30% of patients

  • Hepatic:

    • Immune-mediated hepatitis, elevated transaminases

    • May require corticosteroids or immunosuppressants (e.g., mycophenolate)

  • Dermatologic:

    • Rash, pruritus, vitiligo, severe reactions (toxic epidermal necrolysis rare)

  • Endocrine:

    • Hypophysitis (pituitary inflammation, unique to CTLA-4 inhibitors)

    • Thyroid dysfunction (hypothyroidism, hyperthyroidism)

    • Adrenal insufficiency

    • Diabetes mellitus (autoimmune)

  • Pulmonary:

    • Pneumonitis (rare but severe)

  • Others:

    • Nephritis, pancreatitis, neuropathies

Most immune-mediated adverse events occur within the first 12 weeks of therapy but can occur even months later.

Management of Immune-Related Adverse Events (irAEs)

  • Mild toxicities: Symptomatic treatment, continuation of therapy

  • Moderate to severe toxicities: Withhold treatment, initiate systemic corticosteroids (prednisone 1–2 mg/kg/day or equivalent)

  • Life-threatening toxicities: Permanently discontinue therapy, high-dose corticosteroids, possible use of additional immunosuppressants (infliximab, mycophenolate mofetil)

Precautions

  • Careful monitoring of liver function, thyroid hormones, adrenal function, and glucose levels is mandatory

  • Baseline screening for autoimmune disease

  • Monitoring for delayed toxicities even after cessation of therapy

  • Use with caution in patients with organ transplants (risk of rejection)

Drug Interactions

  • Corticosteroids and immunosuppressants: May blunt the efficacy of CTLA-4 inhibitors if used at baseline. However, they are essential for managing adverse events and should not be avoided when clinically indicated.

  • Live vaccines: Contraindicated during and for several months after therapy due to heightened immune activation and risk of uncontrolled infection.

  • Concurrent checkpoint inhibitors: Combination with anti-PD-1/PD-L1 agents is common and effective but increases toxicity burden.

  • Hepatotoxic or nephrotoxic drugs: Caution due to overlapping toxicities when combined with anti-CTLA-4 agents.

Future Perspectives

While ipilimumab and tremelimumab are the established agents, ongoing research explores:

  • Next-generation CTLA-4 inhibitors with reduced toxicity

  • Bispecific antibodies targeting CTLA-4 and PD-1 simultaneously

  • Biomarker-driven selection to identify patients most likely to benefit (e.g., tumor mutational burden, immune gene signatures)

  • Combination regimens with chemotherapy, targeted therapy, and radiation to enhance efficacy

Summary of Key Drugs and Doses

  • Ipilimumab

    • 3 mg/kg IV every 3 weeks × 4 doses (monotherapy melanoma)

    • 1 mg/kg IV every 3 weeks × 4 doses (in combination with nivolumab)

  • Tremelimumab

    • 300 mg IV single priming dose with durvalumab 1500 mg every 4 weeks (HCC STRIDE regimen)



on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)